Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma

Author： Hellmann Andrzej  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.50, Iss.12, 2011-12, pp. : 781-791

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma

By Quinn David I.  

Clinical Pharmacokinetics, Vol. 48, Iss. 3, 2009-01 ,pp. : 199-209

Adis International

Access to resources Recommend Favorite

Plerixafor: In Patients with Non-Hodgkin's Lymphoma or Multiple Myeloma

By Wagstaff Antona J.  

Drugs, Vol. 69, Iss. 3, 2009-02 ,pp. : 319-326

Adis International

Access to resources Recommend Favorite

Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

By Dresser G.K.  

Clinical Pharmacokinetics, Vol. 38, Iss. 1, 2000-01 ,pp. : 41-57

Adis International

Access to resources Recommend Favorite

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma

By Jamal-Hanjani Mariam   Pettengell Ruth  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1441-1448

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 238-244

John Wiley & Sons Inc

Access to resources Recommend Favorite